论文部分内容阅读
目的评价慢性肾炎患者采取缬沙坦联合阿托伐他汀钙治疗的临床疗效。方法选择2013年9月至2015年9月收治的86例慢性肾炎患者作为研究对象,按随机数字表法分为两组;对照组43例单用阿托伐他汀治疗,观察组43例采取缬沙坦联合阿托伐他汀治疗。对比两组患者治疗前后相关指标变化情况及不良反应发生情况。结果 1在24 h尿蛋白定量、血肌酐、血尿素氮以及C-反应蛋白方面比较,治疗前两组差异未见统计学意义(P>0.05),治疗后两组上述四项指标均有所改善,但观察组改善效果显著优于对照组,差异有统计学意义(P<0.05)。2经积极治疗,观察组出现恶心呕吐1例、乏力厌食1例,不良反应发生率为4.65%;对照组出现恶心呕吐1例、丙氨酸氨基转移酶上升1例、乏力厌食1例,不良反应发生率为6.98%。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论慢性肾炎患者采用缬沙坦联合阿托伐他汀治疗效果显著,能够改善患者肾功能,值得临床应用。
Objective To evaluate the clinical efficacy of valsartan combined with atorvastatin calcium in patients with chronic nephritis. Methods Eighty-six chronic glomerulonephritis patients were selected from September 2013 to September 2015. The patients were divided into two groups according to the random number table. In the control group, 43 cases were treated with atorvastatin alone. In the observation group, 43 cases were treated with Valerian Sartan combined with atorvastatin. Before and after treatment, the change of relevant indicators and the occurrence of adverse reactions were compared between the two groups. Results 1 There was no significant difference in 24 h urinary proteinuria, serum creatinine, blood urea nitrogen and C-reactive protein between the two groups before treatment (P> 0.05) Improve, but the observation group improved significantly better than the control group, the difference was statistically significant (P <0.05). 2 after active treatment, the observation group showed nausea and vomiting in 1 case, fatigue anorexia in 1 case, the incidence of adverse reactions was 4.65%; control group, nausea and vomiting in 1 case, alanine aminotransferase increased in 1 case, fatigue anorexia in 1 case, poor The incidence of the reaction was 6.98%. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The treatment of chronic nephritis with valsartan combined with atorvastatin has a significant effect, which can improve renal function in patients and deserve clinical application.